Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Scott Silveira
Summary
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Description
This randomized, double-blind, placebo-controlled, two-arm crossover trial will compare the effects of two NAD⁺-modulating interventions-EGA® and conventional nicotinamide mononucleotide (NMN) supplementation-on exercise tolerance and metabolic biomarkers in healthy older adults. EGA® is a proprietary formulation composed of three endogenously occurring metabolomic compounds (including NMN) and has been used in prior non-FDA-regulated studies involving human participants. The EGA® arm will involve a twice-daily oral dose of EGA® containing 1000 mg of NMN, while the comparison arm will involve…
Eligibility
- Age range
- 60–80 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Adults aged 60 to 80 years, of any sex * Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study * Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., ch…
Interventions
- Dietary SupplementNMN, betaine, low-dose hydrogen peroxide (EGA)
Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
- Dietary SupplementNicotinamide Mononucleotide (NMN)
Conventional NMN supplement.
- Dietary SupplementPlacebo
Organoleptically matched inert control.
Location
- Medical Office of Dr. Robert Huizenga MDBeverly Hills, California